{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:03:07Z","timestamp":1789596187666,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-12052-5","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:21:25Z","timestamp":1763734885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Plasma and CSF pharmacokinetic characteristics of second-line anti-tuberculosis drugs in a patient with multidrug-resistant tuberculous meningitis"],"prefix":"10.1186","volume":"25","author":[{"given":"Jinlong","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"1","key":"12052_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-024-00504-2","volume":"10","author":"K Dheda","year":"2024","unstructured":"Dheda K, Mirzayev F, Cirillo DM, et al. Multidrug-resistant tuberculosis. Nat Rev Dis Primers. 2024;10(1):22. https:\/\/doi.org\/10.1038\/s41572-024-00504-2. Published 2024 Mar 24.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"12052_CR2","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3390\/vaccines12121397","volume":"12","author":"MJ Nasiri","year":"2024","unstructured":"Nasiri MJ, Lutfy K, Venketaraman V. Challenges of Multidrug-Resistant tuberculosis meningitis: current treatments and the role of glutathione as an adjunct therapy. Vaccines. 2024;12(12):1397. https:\/\/doi.org\/10.3390\/vaccines12121397.","journal-title":"Vaccines"},{"issue":"5","key":"12052_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1474-4422(21)00435-X","volume":"21","author":"J Huynh","year":"2022","unstructured":"Huynh J, Donovan J, Phu NH, Nghia HDT, Thuong NTT, Thwaites GE. Tuberculous meningitis: progress and remaining questions. Lancet Neurol. 2022;21(5):450\u201364. https:\/\/doi.org\/10.1016\/S1474-4422(21)00435-X.","journal-title":"Lancet Neurol"},{"issue":"11","key":"12052_CR4","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/14787210.2018.1540930","volume":"16","author":"RK Garg","year":"2018","unstructured":"Garg RK, Rizvi I, Malhotra HS, Uniyal R, Kumar N. Management of complex tuberculosis cases: a focus on drug-resistant tuberculous meningitis. Expert Rev Anti Infect Ther. 2018;16(11):813\u201331. https:\/\/doi.org\/10.1080\/14787210.2018.1540930.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"10","key":"12052_CR5","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1166\/jbn.2021.3169","volume":"17","author":"W Ma","year":"2021","unstructured":"Ma W, Peng H, Liu K, et al. Efficacy of Dual-Targeting combined Anti-Tuberculosis drug delivery system in the treatment of tuberculous meningitis. J Biomed Nanotechnol. 2021;17(10):2034\u201342. https:\/\/doi.org\/10.1166\/jbn.2021.3169.","journal-title":"J Biomed Nanotechnol"},{"issue":"7","key":"12052_CR6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1086\/605576","volume":"49","author":"JW Alffenaar","year":"2009","unstructured":"Alffenaar JW, van Altena R, B\u00f6kkerink HJ, et al. Pharmacokinetics of Moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis. 2009;49(7):1080\u20132. https:\/\/doi.org\/10.1086\/605576.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"12052_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","volume":"74","author":"A Alsultan","year":"2014","unstructured":"Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74(8):839\u201354. https:\/\/doi.org\/10.1007\/s40265-014-0222-8.","journal-title":"Drugs"},{"key":"12052_CR8","volume-title":"WHO consolidated guidelines on tuberculosis: module 4: treatment - Drug-Resistant tuberculosis treatment","author":"WHO Guidelines Approved by the Guidelines Review Committee","year":"2020","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. WHO consolidated guidelines on tuberculosis: module 4: treatment - Drug-Resistant tuberculosis treatment. Geneva: World Health Organization; 2020."},{"key":"12052_CR9","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.2147\/IDR.S401281","volume":"16","author":"Z Liang","year":"2023","unstructured":"Liang Z, Liao W, Chen Q, et al. Pharmacokinetics of antituberculosis drugs in plasma and cerebrospinal fluid in a patient with Pre-Extensive drug resistant tuberculosis meningitis. Infect Drug Resist. 2023;16:1669\u201376. https:\/\/doi.org\/10.2147\/IDR.S401281.","journal-title":"Infect Drug Resist"},{"issue":"11","key":"12052_CR10","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.3390\/pharmaceutics15112554","volume":"15","author":"A Rusu","year":"2023","unstructured":"Rusu A, Moga IM, Uncu L, Hancu G. The role of Five-Membered heterocycles in the molecular structure of antibacterial drugs used in therapy. Pharmaceutics. 2023;15(11):2554. https:\/\/doi.org\/10.3390\/pharmaceutics15112554.","journal-title":"Pharmaceutics"},{"issue":"8","key":"12052_CR11","doi-asserted-by":"publisher","first-page":"e0309352","DOI":"10.1371\/journal.pone.0309352","volume":"19","author":"D Requena","year":"2024","unstructured":"Requena D, Supo-Escalante RR, Sheen P, Zimic M. Studying the dynamics of the drug processing of Pyrazinamide in Mycobacterium tuberculosis. PLoS ONE. 2024;19(8):e0309352. https:\/\/doi.org\/10.1371\/journal.pone.0309352.","journal-title":"PLoS ONE"},{"issue":"6","key":"12052_CR12","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/jac\/dkac067","volume":"77","author":"CM Upton","year":"2022","unstructured":"Upton CM, Steele CI, Maartens G, et al. Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). J Antimicrob Chemother. 2022;77(6):1720\u20134. https:\/\/doi.org\/10.1093\/jac\/dkac067.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"12052_CR13","doi-asserted-by":"publisher","first-page":"106875","DOI":"10.1016\/j.ijantimicag.2023.106875","volume":"62","author":"W Guo","year":"2023","unstructured":"Guo W, Hu M, Xu N, et al. Concentration of contezolid in cerebrospinal fluid and serum in a patient with tuberculous meningoencephalitis: A case report. Int J Antimicrob Agents. 2023;62(2):106875. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106875.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"12052_CR14","doi-asserted-by":"publisher","first-page":"e00641","DOI":"10.1128\/AAC.00641-18","volume":"62","author":"WA Alghamdi","year":"2018","unstructured":"Alghamdi WA, Al-Shaer MH, Peloquin CA. Protein binding of First-Line antituberculosis drugs. Antimicrob Agents Chemother. 2018;62(7):e00641\u201318. https:\/\/doi.org\/10.1128\/AAC.00641-18.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12052-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12052-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12052-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:21:26Z","timestamp":1763734886000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-12052-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12052"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12052-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine. Institutional approval for the publication of anonymized clinical details was obtained from Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine in accordance with local regulations and ethical guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s parents for publication of this case report and accompanying statistics. Identifying information has been anonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1632"}}